[Federal Register Volume 77, Number 186 (Tuesday, September 25, 2012)]
[Notices]
[Pages 58999-59000]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-23543]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-D-0938]
Draft Guidance for Industry on Abbreviated New Drug Applications:
Stability Testing of Drug Substances and Products; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``ANDAs:
Stability Testing of Drug Substances and Products.'' FDA is
recommending that generic drug manufacturers follow the stability
testing recommendations in the International Conference on
Harmonisation (ICH) guidances Q1A(R2) through Q1E. The use of these ICH
recommendations will standardize FDA's stability testing policies,
which will help make the abbreviated new
[[Page 59000]]
drug application (ANDA) review process more efficient.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by December 24, 2012.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Radhika Rajagopalan, Center for Drug
Evaluation and Research, Food and Drug Administration, 7500 Standish
Pl., MPN2, Rm. 243, HFD-640, Rockville, MD 20855, 240-276-8546.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``ANDAs: Stability Testing of Drug Substances and Products.''
Because of increases in numbers of ANDAs and their complexity, the FDA
is considering standardizing stability testing policies by adopting
recommendations in the following stability related ICH guidances: (1)
``Q1A (R2) Stability Testing of New Drug Substances and Products,''
November 2003; (2) ``Q1B Photostability Testing of New Drug Substances
and Products,'' November 1996; (3) ``Q1C Stability Testing for New
Dosage Forms,'' November 1996; (4) ``Q1D Bracketing and Matrixing
Designs for Stability Testing of New Drug Substances and Products,''
January 2003; and (5) ``Q1E Evaluation of Stability Data,'' June 2004.
FDA is also considering adopting the ICH outlined definitions,
glossaries, references, and attachments.
Although the ICH stability guidances were developed for new drug
applications to ensure the stability of new drug substances and
products, FDA believes the recommendations provided in the ICH
guidances on stability testing are appropriate for ANDAs as well. This
guidance contains FDA's recommendation that ANDAs submitted pursuant to
section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)), and the drug master files that support ANDAs, follow the
stability recommendations provided in the ICH stability guidances.
This guidance also replaces stability study storage condition
recommendations made in an August 18, 1995, letter that the Center for
Drug Evaluation and Research's (CDER's) Office of Generic Drugs (OGD)
sent to all ANDA applicants, which is available on CDER's Web site:
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064995.htm. The letter stated that OGD would accept ANDAs
with the ICH recommended long term room temperature conditions for
stability studies, 25 2[deg]C, 60 5 percent
RH.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on stability
testing of drug substances and products for ANDAs. It does not create
or confer any rights for or on any person and does not operate to bind
FDA or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday, and will
be posted to the docket at http://www.regulations.gov.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.
Dated: September 18, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-23543 Filed 9-24-12; 8:45 am]
BILLING CODE 4160-01-P